Cipla Grants Stock Options and Employee Stock Appreciation Rights under Two Schemes
Cipla Limited has announced grants related to two internal incentive programs: the Employee Stock Option Scheme 2013 A (ESOS 2013-A) and the Cipla Employee Stock Appreciation Rights Scheme 2021 (ESAR 2021). These grants form part of the company's employee stock benefit plans.The board meeting confirmed the details of the allocations across both schemes, specifying the number of options and ESARs granted along with their associated timelines.
Details regarding the stock option and ESAR grants are provided below:
| Scheme | Type of Incentive | Number Granted | Vesting/Exercise Period Details |
|---|---|---|---|
| ESOS 2013-A | Stock Options | 5,530 | 2 years from the grant date; 5 years from vesting date for exercise |
| ESAR 2021 | Employee Stock Appreciation Rights (ESARs) | 19,179 | 3 years graded vesting; 5 years from vesting date for exercise |
The allocations cover both stock options and Employee Stock Appreciation Rights under the specified schemes. The grants are subject to the outlined vesting and exercise periods for each respective scheme.
CIPLA Stock Price Movement
Shares of Cipla Limited are slipping by 2.70% in live trading as of 2:07 PM, with the stock currently marking ₹1376.9. The pharmaceutical giant trades within a wide intraday range, having reached a high of ₹1426.9 but finding support near the day's low of ₹1366.1.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.